Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    RTOG 0617
Show Display Options
RSS Create an RSS feed from your search for:
RTOG 0617
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Conditions: Lung Cancer;   Radiation Toxicity
Interventions: Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: 3-dimensional conformal radiation therapy

Indicates status has not been verified in more than two years